Dr. Hamlin on Key Points of a Study on Cerdulatinib in Non-Hodgkin Lymphoma

Paul A. Hamlin, MD
Published: Monday, Nov 06, 2017



Paul A. Hamlin, MD, chief of the Medical Oncology Service at Memorial Sloan Kettering Cancer Center, discusses a phase II study investigating cerdulatinib in patients with non-Hodgkin lymphoma.

There is an increasing amount of oral agents that will be available for patients with a good safety margin and the possibility of combinations, states Hamlin.

According to Hamlin, we are entering an era where the understanding of biology will allow us to address the patients


Paul A. Hamlin, MD, chief of the Medical Oncology Service at Memorial Sloan Kettering Cancer Center, discusses a phase II study investigating cerdulatinib in patients with non-Hodgkin lymphoma.

There is an increasing amount of oral agents that will be available for patients with a good safety margin and the possibility of combinations, states Hamlin.

According to Hamlin, we are entering an era where the understanding of biology will allow us to address the patients



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: Key Questions for the Use of Immunotherapy Throughout the Disease Continuum for NSCLC in an Era of Rapid DevelopmentSep 29, 20181.5
Provider and Caregiver Connection™: Addressing Patient Concerns While Managing GlioblastomaSep 29, 20182.0
Publication Bottom Border
Border Publication
x